TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11401812

Group type: COMPARATOR
Intervention: Signature group (control)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Non-signature group (experimental)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups (signature and non-signature)
Number of subjects: 110
Study: 9260215

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with house dust mite extract (D.pt.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8280542

Group type: EXPERIMENTAL
Intervention: 28-gauge spinal catheters
Number of subjects: 68
Study: 3566442

Group type: EXPERIMENTAL
Intervention: Atropine sulfate 0.3%
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Tropicamide 0.5%
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 29412458

Group type: EXPERIMENTAL
Intervention: Oliceridine (TRV130) administered in doses ranging from 0.5 to 4 mg every 3-4 hours during the phase 2 study.
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Oliceridine (TRV130) administered in single doses ranging from 0.15 to 7 mg and multiple doses ranging from 0.4 to 4.5 mg every 4-6 hours during the phase 1 study.
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo group during the phase 2 study.
Number of subjects: 410
Study: 27074824

Group type: EXPERIMENTAL
Intervention: Finerenone (2.5, 5, 7.5, 10 or 15 mg, up-titrated to 5, 10, 15, 20, or 20 mg, respectively, on day 30)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Eplerenone (25 mg every other day, increased to 25 mg o.d. on day 30, and 50 mg on day 60)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 72
Study: 24113927

Group type: EXPERIMENTAL
Intervention: Menthol smokers
Number of subjects: 166

Group type: COMPARATOR
Intervention: Nonmenthol smokers
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Menthol smokers who quit
Number of subjects: 166
Study: 22954020

Group type: EXPERIMENTAL
Intervention: 2-back test
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0-back test
Number of subjects: 18
Study: 20826243

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose followed by 75 mg/d) + Aspirin (75 mg/d for first 21 days)
Number of subjects: 5100

Group type: COMPARATOR
Intervention: Aspirin (75 mg/d) alone
Number of subjects: 5100
Study: 19030110

Group type: EXPERIMENTAL
Intervention: Relative Risk Reduction (RRR)
Number of subjects: 770

Group type: COMPARATOR
Intervention: Absolute Risk Reduction, Number Needed to Treat, Event Rates, Tablets Needed to Take, Natural Frequencies
Number of subjects: 770
Study: 16649375

Group type: EXPERIMENTAL
Intervention: Mother's milk
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Ethyl alcohol 96%
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 312
Study: 12815479

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (high-dose therapy only)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (contaminated samples)
Number of subjects: 23
Study: 11101185

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 88 microg BID
Number of subjects: 437

Group type: COMPARATOR
Intervention: Zafirlukast 20 mg BID
Number of subjects: 437
Study: 9159696

Group type: EXPERIMENTAL
Intervention: Brief interventions
Number of subjects: 12

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 12
Study: 8513521

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 30
Study: 3317128

Group type: EXPERIMENTAL
Intervention: Steri-Strip tape suture
Number of subjects: 264

Group type: COMPARATOR
Intervention: Conventional continuous 3‐o or 4‐o Dermalon suture
Number of subjects: 264
Study: 31135929

Group type: EXPERIMENTAL
Intervention: Pelvic and rad-board lead shields during coronary angiography (CA) procedures
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Pelvic and rad-board lead shields during angioplasty (PCI) procedures
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Pelvic and rad-board lead shields
Number of subjects: 418
Study: 29338824

Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training (IE)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training with whey protein isolate supplement (IE + WPI)
Number of subjects: 22
Study: 25965871

Group type: EXPERIMENTAL
Intervention: Social-evaluative context (SET) stressor
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-evaluative context (non-SET) stressor
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Trait rumination
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Gender differences in rumination
Number of subjects: 144
Study: 23601460

Group type: EXPERIMENTAL
Intervention: Tobramycin dexamethasone eye ointment
Number of subjects: 148

Group type: COMPARATOR
Intervention: Tobramycin eye ointment (Control)
Number of subjects: 148
Study: 21369670

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 19101099

Group type: EXPERIMENTAL
Intervention: Motivation Enhancement Therapy (MET)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 200
Study: 17060388

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 500
Study: 12735660

Group type: EXPERIMENTAL
Intervention: Cumulative dose regimen of formoterol (9 + 9 + 18 microg, total 36 microg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single high dose of formoterol (36 microg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both treatment regimens (cumulative and single high dose)
Number of subjects: 16
Study: 10620003

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (EPA 3.2 g, DHA 2.4 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8841150

Group type: EXPERIMENTAL
Intervention: Arecoline (4 mg/day, n = 6)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Arecoline (16 mg/day, n = 3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Arecoline (optimal dose for memory enhancement)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Arecoline (0.5 to 40 mg/day during multiple-dose infusions)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 15
Study: 1627957

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 6435644

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate spray (2 sprays, 2.5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sublingual glyceryl trinitrate (0.3 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ordinary isosorbide dinitrate tablet (5 mg)
Number of subjects: 9
Study: 30895698

Group type: EXPERIMENTAL
Intervention: Narrow diameter implants (NDIs) (< 3.3 mm)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Regular diameter implants (RDIs) (4.1 mm)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Narrow diameter implants (NDIs) and Regular diameter implants (RDIs)
Number of subjects: 86
Study: 30189773

Group type: EXPERIMENTAL
Intervention: ShcA expression measured by immunofluorescence in kidney tissues from LN patients
Number of subjects: 92

Group type: COMPARATOR
Intervention: ShcA expression in primary and other secondary MN
Number of subjects: 92
Study: 26630947

Group type: EXPERIMENTAL
Intervention: Single-Incision Sling (SIS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Transobturator Sling (TOT)
Number of subjects: 93
Study: 24190907

Group type: EXPERIMENTAL
Intervention: Real interpersonal touch (brief touch on the shoulder by a female experimenter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated interpersonal touch (holding a teddy bear)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated interpersonal touch (higher value estimates of a teddy bear)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (cardboard box)
Number of subjects: 0
Study: 22547887

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 50
Study: 20580303

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham needle control
Number of subjects: 41
Study: 17123696

Group type: EXPERIMENTAL
Intervention: PCOS patients
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PCOS patients without insulin resistance
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PCOS patients with insulin resistance
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 16036044

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conivaptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loop diuretics
Number of subjects: 0
Study: 11987088

Group type: EXPERIMENTAL
Intervention: Laparoscopic varicocelectomy (LV)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Open varicocelectomy (OV)
Number of subjects: 654
Study: 9607623

Group type: EXPERIMENTAL
Intervention: Drain group
Number of subjects: 115

Group type: COMPARATOR
Intervention: No-drain group
Number of subjects: 115
Study: 9144613

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol based bisacodyl suppository (PEGBS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional bisacodyl suppository based in hydrogenated vegetable oil (HVOBS)
Number of subjects: 19
Study: 2250039

Group type: EXPERIMENTAL
Intervention: Home interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postal questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical records
Number of subjects: 0
Study: 7011349

Group type: COMPARATOR
Intervention: salbutamol (0.15 micrograms kg‐1 min‐1 for 30 min)
Number of subjects: 4

Group type: COMPARATOR
Intervention: aminophylline (0.2 mg kg‐1 min‐1 for 30 min)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: salbutamol, salbutamol (SS)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: aminophylline, salbutamol (AS)
Number of subjects: 4
Study: 31997718

Group type: EXPERIMENTAL
Intervention: Fresh Water Bath (FWB)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Salt Water Bath (SWB)
Number of subjects: 11
Study: 30144242

Group type: EXPERIMENTAL
Intervention: Conventional treatment (antimycotic or steroid) and probiotic
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study: 28898920

Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy
Number of subjects: 337

Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 337
Study: 25679130

Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 157
Study: 25438680

Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiamylal (1.5 mg/kg)
Number of subjects: 40
Study: 22909145

Group type: EXPERIMENTAL
Intervention: EE 0.03 mg/drospirenone 3 mg/levomefolate calcium 0.451 mg (SAFYRAL®)
Number of subjects: 45

Group type: COMPARATOR
Intervention: EE 0.03 mg/drospirenone 3 mg (Yasmin®)
Number of subjects: 45

Group type: COMPARATOR
Intervention: levomefolate calcium 0.451 mg
Number of subjects: 45
Study: 20099307

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN) group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal controls (NC) group
Number of subjects: 25
Study: 18056882

Group type: EXPERIMENTAL
Intervention: Push-button response method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hand-raise response method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Verbal response method
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All response methods
Number of subjects: 30
Study: 16230721

Group type: EXPERIMENTAL
Intervention: Inhaled insulin plus oral agents (n = 103)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Inhaled insulin alone (n = 104)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Oral agent therapy alone (n = 99)
Number of subjects: 309
Study: 12173326

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (EMP) as first-line therapy
Number of subjects: 386

Group type: COMPARATOR
Intervention: No further therapeutic intervention (Control group)
Number of subjects: 386
Study: 10203381

Group type: EXPERIMENTAL
Intervention: ZDV plus ddl
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: ZDV plus ddC
Number of subjects: 1280

Group type: COMPARATOR
Intervention: ZDV alone
Number of subjects: 1280
Study: 7781349

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (2 g IV)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (IV)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (2 g IV) in severe group
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (IV) in severe group
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (2 g IV) in moderate group
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (IV) in moderate group
Number of subjects: 135
Study: 2278325

Group type: EXPERIMENTAL
Intervention: Continuous interpleural analgesia with 20 ml bupivacaine 0.5% with adrenaline 5 micrograms/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous interpleural analgesia with bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined administration of interpleural bupivacaine and systemic morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine regimen
Number of subjects: 0
Study: 758795

Group type: EXPERIMENTAL
Intervention: Training in coping and social skills (behavioral training)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 121
Study: 31794324

Group type: EXPERIMENTAL
Intervention: Decitabine + ATRA
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Decitabine + Valproate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Decitabine alone
Number of subjects: 200
Study: 31702761

Group type: EXPERIMENTAL
Intervention: Cranberry +health™ cranberry supplement (cranberry chew)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo chew
Number of subjects: 20
Study: 29090491

Group type: EXPERIMENTAL
Intervention: MRI Group (MG) - Accent MRI™ conditional pacing system, n = 140
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control Group (CG) - Standard device interrogation and clinical evaluation, n = 143
Number of subjects: 283
Study: 24924522

Group type: EXPERIMENTAL
Intervention: Soyabean meal (SB)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Whey proteins (WP)
Number of subjects: 18
Study: 23541423

Group type: EXPERIMENTAL
Intervention: cilostazol 200 mg/day
Number of subjects: 510

Group type: COMPARATOR
Intervention: no medication (control group)
Number of subjects: 510
Study: 21692286

Group type: EXPERIMENTAL
Intervention: Meridian‐collateral electric information therapy combined with pricking and cupping
Number of subjects: 200

Group type: COMPARATOR
Intervention: Acyclovir administered orally
Number of subjects: 200
Study: 19747869

Group type: EXPERIMENTAL
Intervention: Supervised home-based exercise (3 sessions a week of stationary cycling) for 10 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group maintained usual daily activity
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supervised home-based exercise
Number of subjects: 12
Study: 16697308

Group type: EXPERIMENTAL
Intervention: Para-Hisian pacing
Number of subjects: 16

Group type: COMPARATOR
Intervention: Right apical pacing
Number of subjects: 16
Study: 15110211

Group type: EXPERIMENTAL
Intervention: Post-infarction left atrial remodeling
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Relation of left atrial remodeling to left ventricular remodeling
Number of subjects: 514
Study: 14750569

Group type: EXPERIMENTAL
Intervention: Intracameral or intravitreal injection of 0.1 mL antibiotic (40 microg gentamicin and 45 microg clindamycin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balanced saline solution (BSS) injection
Number of subjects: 60
Study: 9662313

Group type: EXPERIMENTAL
Intervention: Daily placement of prostaglandin gel
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Daily membrane stripping
Number of subjects: 105

Group type: COMPARATOR
Intervention: Daily cervical examinations
Number of subjects: 105
Study: 10208998

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/d) and colestipol (30 g/d)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Niacin (4 g/d) and colestipol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional therapy with placebo alone or with colestipol
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 88
Study: 2142911

Group type: EXPERIMENTAL
Intervention: Picotamide (600 mg daily for six months)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (identical to picotamide)
Number of subjects: 51
Study: 333540

Group type: EXPERIMENTAL
Intervention: Feprazone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 24
Study: 31554917

Group type: EXPERIMENTAL
Intervention: MO-lower-IR
Number of subjects: 68

Group type: COMPARATOR
Intervention: MO-higher-IR
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: MO-metf-T2DM
Number of subjects: 68
Study: 31781825

Group type: EXPERIMENTAL
Intervention: Credé maneuver
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-Credé maneuver
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Credé maneuver (mixed urinary incontinence)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-Credé maneuver (mixed urinary incontinence)
Number of subjects: 148
Study: 27197120

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (vitamin H)
Number of subjects: 11
Study: 24374394

Group type: EXPERIMENTAL
Intervention: Local anesthetic solution (LAS) applied to the columella (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Local anesthetic solution (LAS) applied to the nasal dorsum (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Local anesthetic solution (LAS) applied to the nasal dorsum followed by LAS to the columella after 10 minutes (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Number of subjects: 47
Study: 23400883

Group type: EXPERIMENTAL
Intervention: Advocacy intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 21537645

Group type: EXPERIMENTAL
Intervention: Preventive acupuncture (PA) group, n = 12
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CT), n = 12
Number of subjects: 24
Study: 19663305

Group type: EXPERIMENTAL
Intervention: inulin fortified spoon yoghurt
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: kefir drink
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: drinking yoghurt
Number of subjects: 76
Study: 17086465

Group type: EXPERIMENTAL
Intervention: 4:00 PM inhalation of 4.5% saline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 4:00 AM inhalation of 4.5% saline
Number of subjects: 18
Study: 15583260

Group type: EXPERIMENTAL
Intervention: Safe storage of medicines
Number of subjects: 3906

Group type: EXPERIMENTAL
Intervention: Use of smoke alarms
Number of subjects: 3906

Group type: EXPERIMENTAL
Intervention: Storage of sharp objects
Number of subjects: 3906

Group type: EXPERIMENTAL
Intervention: Awareness of availability of fireguards
Number of subjects: 3906

Group type: EXPERIMENTAL
Intervention: Awareness of availability of stair gates
Number of subjects: 3906

Group type: EXPERIMENTAL
Intervention: Awareness of availability of cupboard locks
Number of subjects: 3906

Group type: EXPERIMENTAL
Intervention: Need for help fitting fireguards
Number of subjects: 3906

Group type: EXPERIMENTAL
Intervention: Need for help fitting stair gates
Number of subjects: 3906

Group type: EXPERIMENTAL
Intervention: Need for help fitting cupboard locks
Number of subjects: 3906
Study: 11704585

Group type: EXPERIMENTAL
Intervention: Turbuhaler (0.25 mg terbutaline)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Turbuhaler (0.5 mg terbutaline)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: pMDI (0.25 mg terbutaline)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: pMDI (0.5 mg terbutaline)
Number of subjects: 13
Study: 9470838

Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 (version 1) questionnaire assessing physical functioning, role functioning, global health/QoL scales, and a single pain item.
Number of subjects: 638
Study: 8188891

Group type: EXPERIMENTAL
Intervention: Fumaric acid derivatives
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2917596

Group type: EXPERIMENTAL
Intervention: 5-Methoxypsoralen (5-MOP) 40 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31696603

Group type: EXPERIMENTAL
Intervention: Mid-dose (PHEN/TPM 7.5 mg/46 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Top-dose (PHEN/TPM 15 mg/92 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mid-dose
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Top-dose
Number of subjects: 42
Study: 30649270

Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP)
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Dual-Chamber Pacing (DDDR)
Number of subjects: 1166
Study: 28520768

Group type: EXPERIMENTAL
Intervention: Mobile phone reminders and peer counseling
Number of subjects: 242
Study: 25786566

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 54
Study: 23450015

Group type: EXPERIMENTAL
Intervention: Durasul highly cross‐linked polyethylene
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sulene polyethylene
Number of subjects: 90
Study: 21254055

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30